Xudong Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xudong Zeng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Deping Wang
Department of Cardiology, the First hospital of Shanxi Medical University, and MOE Key Laboratory of Cellular Physiology at Shanxi Medical University, Taiyuan, China
1 shared publication Dong Li
1 shared publication- Haitao Yang
ShanghaiTech University
1 shared publication Meng Zhang
1 shared publicationMengmeng Lin
1 shared publication- Mengmeng Lin
Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China
1 shared publication
Latest Publications
- 4 August 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 833
Structural basis for the inhibition of HKU8 main protease by nirmatrelvir and ensitrelvir
- 4 August 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 833
Structural basis for the inhibition of HKU8 main protease by nirmatrelvir and ensitrelvir
- Open Access
- 5 July 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-7
Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
SARS-CoV-2 poses an unprecedented threat to the world as the causative agent of the COVID-19 pandemic. Among a handful of therapeutics developed for the prevention and treatment of SARS-CoV-2 infection, ensitrelvir is the first noncovalent and nonpeptide oral inhibitor targeting the main protease (Mpro) of SARS-CoV-2, which recently received emergency regulatory approval in Japan. Here we determined a 1.8-Å structure of Mpro in complex with ensitrelvir, which revealed that ensitrelvir targets the substrate-binding pocket of Mpro, specifically recognizing its S1, S2, and S1' subsites. Further, our comprehensive biochemical and structural data have demonstrated that even though ensitrelvir and nirmatrelvir (an FDA-approved drug) belong to different types of Mpro inhibitors, both of them remain to be effective against Mpros from all five SARS-CoV-2 variants of concern, suggesting Mpro is a bona fide broad-spectrum target. The molecular mechanisms uncovered in this study provide basis for future inhibitor design.
- 5 July 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-7
Open AccessMolecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
SARS-CoV-2 poses an unprecedented threat to the world as the causative agent of the COVID-19 pandemic. Among a handful of therapeutics developed for the prevention and treatment of SARS-CoV-2 infection, ensitrelvir is the first noncovalent and nonpeptide oral inhibitor targeting the main protease (Mpro) of SARS-CoV-2, which recently received emergency regulatory approval in Japan. Here we determined a 1.8-Å structure of Mpro in complex with ensitrelvir, which revealed that ensitrelvir targets the substrate-binding pocket of Mpro, specifically recognizing its S1, S2, and S1' subsites. Further, our comprehensive biochemical and structural data have demonstrated that even though ensitrelvir and nirmatrelvir (an FDA-approved drug) belong to different types of Mpro inhibitors, both of them remain to be effective against Mpros from all five SARS-CoV-2 variants of concern, suggesting Mpro is a bona fide broad-spectrum target. The molecular mechanisms uncovered in this study provide basis for future inhibitor design.